通过阿尔茨海默氏病小鼠模型的突触调制途径通过金纳米粒子介导的阿弗泽林传递来增强认知和记忆功能
Ju Hee Mun1,2, Min Jun Jang1,3, Won Seok Kim1,4
1Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
ACS chemical neuroscience
|February 20, 2025
概括
装有afzelin的金纳米颗粒显示在小鼠中增强了对阿尔茨海默氏症 (AD) 的神经保护. 这种组合疗法可以改善认知和拯救神经元细胞,为神经退行性疾病提供有前途的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 纳米技术纳米技术
背景情况:
- 黄金纳米粒子 (AuNPs) 用于用于神经退行性疾病的药物输送.
- 亚兹林是一种天然化合物,具有治疗潜力,但面临着生产率低等局限性.
- 将AuNP与afzelin结合使用可能会提高治疗效果,克服天然化合物的局限性.
研究的目的:
- 为了研究装载着阿兹林 (AuNP-afzelin) 的金纳米颗粒的神经保护作用.
- 在阿尔茨海默病 (AD) 的小鼠模型中,比较AuNP-afzelin治疗与单剂afzelin治疗的疗效.
- 探索AuNP-afzelin神经保护作用的潜在机制.
主要方法:
- 在斯科波拉胺诱导的AD小鼠中,AuNP-afzelin和afzelin的中央管理.
- 行为测试评估认知和记忆.
- 分析海马标记物,包括BDNF-pCREB-pAkt信号传递,长期强化和双皮质素 (DCX) 表达.
主要成果:
- 与单独使用afzelin相比,AuNP-afzelin治疗显著改善了认知和记忆功能.
- AuNP-afzelin表现出卓越的神经保护作用,拯救成熟的神经元细胞.
- 组合疗法有效地恢复了胆固醇功能障碍,并调节了关键的神经保护信号通路.
结论:
- AuNP-afzelin代表了一种有效的治疗策略,用于减轻神经退行性疾病中的认知障碍.
- 黄金纳米粒子增强了afzelin在神经学应用中的生物可用性和有效性.
- 这种方法为治疗认知衰退的药物开发提供了新的方向.
更多相关视频
07:07Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
18.9K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.0K
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:22Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
01:26Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429